CD98 RNAi Summary
| Specificity |
solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 (SLC3A2), transcript variant 1, mRNA
|
| Gene |
SLC3A2
|
Applications/Dilutions
| Application Notes |
This RNAi causes protein knockdown.
|
|
| Publications |
|
Packaging, Storage & Formulations
| Storage |
Store at -20C. Avoid freeze-thaw cycles.
|
Notes
This product is produced by and distributed for Abnova, a company based in Taiwan.
Alternate Names for CD98 RNAi
- 4F2
- 4F2hc
- 4T2HC
- antigen identified by monoclonal antibodies 4F2, TRA1.10, TROP4, and T43,4F2HC
- CD98 antigen
- CD98 heavy chain
- CD98
- CD98HC
- heavy chain
- Lymphocyte activation antigen 4F2 large subunit
- MDU1antigen defined by monoclonal 4F2, heavy chain
- monoclonal 44D7
- NACAE4F2 cell-surface antigen heavy chain
- SLC3A2
- solute carrier family 3 (activators of dibasic and neutral amino acidtransport), member 2,4F2 heavy chain antigen
Background
Chimera RNA interference (chimera RNAi) is process by which small interfering RNA/DNA chimera triggers the destruction of mRNA for the original gene. The discovery work, design, and application of chimera RNAi has been pioneered by Professor Kaoru Saigo and Dr. Kumiko Ui-Tei at the University of Tokyo. Chimera RNAi has many advantages over the conventional siRNAs. First, it has been demonstrated to have reliable knock-down for over 10,000 human genes. Because the human genome is composed of an intricate, genetic network, chimera RNAis unique design has successfully obviated the off-target effects including microRNA-based influence. Another advantage of the chimera RNAi technology is its effectiveness at low concentrations (0.5nM to 5nM); only mRNA is destroyed so genomic genes are not affected. Finally, having both the sense and anti-sense strands consisting RNA/DNA chimera, it offers much greater compound stability for streamlining in vitro and in vivo assays and applications while minimizing interferon induction and other adverse reactions.
